Hepatoprotective Effects of Albumin-Encapsulated Nanoparticles of a Curcumin Derivative COP-22 against Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Injury in Mice
Abstract
:1. Introduction
2. Results
2.1. Preparation and Characterization of 22 NPs
2.1.1. The Particle Size, Morphology, and Stability
2.1.2. Solid State Characterization
2.1.3. Binding Properties of COP-22 with BSA
2.2. In Vitro Study
2.2.1. Inhibitory Effect of 22 NPs on the LPS-Induced NO and ROS Production
2.2.2. Effect of Cellular Uptake Activity
2.3. In Vivo Study
2.3.1. Pathological Histology of Liver Tissues
2.3.2. Effects of 22 NPs on Liver Function-Related Indexes in Serum of Mice
2.3.3. The 22 NPs Attenuated LPS/D-GalN-Induced Inflammation in LPS/D-GalN-Induced Mice
2.3.4. The 22 NPs Attenuated LPS/D-GalN-Induced Oxidative Stress in LPS/D-GalN-Induced Mice
2.3.5. The 22 NPs Alleviated LPS/D-GalN-Induced Hepatic Apoptosis in LPS/D-GalN-Induced Mice
2.3.6. Biodistribution Study
3. Conclusions
4. Materials and Methods
4.1. Materials
4.2. Preparation of 22 NPs
4.3. Characteristics of 22 NPs
4.3.1. Particle Size, Zeta Potential, and PDI
4.3.2. Encapsulation Efficiency (EE) and Drug-Loading Content (DLC)
- EE (%) = (Total amount of the bound drug in the NPs)/(Total feed amount of the drug) × 100%
- = (Total feed amount of the drug—the amount of free drug)/(Total feed amount of the drug) × 100%
- DLC (%)
- = (Total amount of the bound drug in the NPs)/(Total weight of the NPs) × 100%
- = (Total feed amount of the drug—the amount of free drug)/(Total weight of the NPs) × 100%.
4.3.3. X-ray Diffraction (XRD)
4.4. Molecular Docking Studies
4.5. Cell Culture
4.6. Measurement of NO Production
4.7. Determination of Intracellular ROS Levels
4.8. Cellular Uptake Activity
4.9. Animals
4.10. Induction of Acute Hepatitis in Mice and Treatment
4.11. Measurement of the Levels of AST and ALT
4.12. Cytokine Determination
4.13. NO Assay of Liver Tissues
4.14. MPO Assay
4.15. MDA Assay
4.16. CAT Assay
4.17. Histopathology Analysis
4.18. TUNEL Assay
4.19. In Vivo Pharmacokinetics and Biodistribution
4.20. Western Blot Analysis
4.21. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Knolle, P.A.; Wohlleber, D. Immunological functions of liver sinusoidal endothelial cells. Cell Mol. Immunol. 2016, 13, 347–353. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- McDonald, B.; Kubes, P. Innate immune cell trafficking and function during sterile inflammation of the liver. Gastroenterology 2016, 151, 1087–1095. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Montrief, T.; Koyfman, A.; Long, B. Acute liver failure: A review for emergency physicians. Am. J. Emerg. Med. 2019, 37, 329–337. [Google Scholar] [CrossRef] [PubMed]
- Stravitz, R.T.; Lee, W.M. Acute liver failure. Lancet 2019, 394, 869–881. [Google Scholar] [CrossRef]
- Starzl, T.E.; Iwatsuki, S.; Van Thiel, D.H.; Gartner, J.C.; Zitelli, B.J.; Malatack, J.J.; Schade, R.R.; Shaw, B.W., Jr.; Hakala, T.R.; Rosenthal, J.T.; et al. Evolution of liver transplantation. Hepatology 1982, 2, 614–636. [Google Scholar] [CrossRef] [Green Version]
- Kandiah, P.A.; Olson, J.C.; Subramanian, R.M. Emerging strategies for the treatment of patients with acute hepatic failure. Curr. Opin. Crit. Care 2016, 22, 142–151. [Google Scholar] [CrossRef]
- Sedhom, D.; Souza, M.D.; John, E.; Rustgi, V. Viral hepatitis and acute liver failure: Still a problem. Clin. Liver Dis. 2018, 22, 289–300. [Google Scholar] [CrossRef]
- Hamesch, K.; Borkham-Kamphorst, E.; Strnad, P.; Weiskirchen, R. Lipopolysaccharide-induced inflammatory liver injury in mice. Lab. Anim. 2015, 49, 37–46. [Google Scholar] [CrossRef]
- Tunon, M.J.; Alvarez, M.; Culebras, J.M.; Gonzalez-Gallego, J. An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. World J. Gastroenterol. 2009, 15, 3086–3098. [Google Scholar] [CrossRef]
- Zeng, X.K.; Liu, G.G.; Peng, W.W.; He, J.M.; Cai, C.X.; Xiong, W.; Chen, S.S.; Yang, M.X.; Dong, Z.J. Combined deficiency of SLAMF8 and SLAMF9 prevents endotoxin-induced liver inflammation by downregulating TLR4 expression on macrophages. Cell. Mol. Immunol. 2020, 17, 153–162. [Google Scholar] [CrossRef]
- Stuart, W.D.; Kulkarni, R.M.; Gray, J.K.; Vasiliauskas, J.; Leonis, M.A.; Waltz, S.E. Ron receptor regulates Kupffer cell-dependent cytokine production and hepatocyte survival following endotoxin exposure in mice. Hepatology 2011, 53, 1618–1628. [Google Scholar] [CrossRef] [Green Version]
- Vergadi, E.; Vaporidi, K.; Tsatsanis, C. Regulation of endotoxin tolerance and compensatory anti-inflammatory response syndrome by non-coding RNAs. Front. Immunol. 2018, 9, 2705. [Google Scholar] [CrossRef] [Green Version]
- An, J.F.; Harms, C.; Lattig-Tunnemann, G.; Sellge, G.; Mandic, A.D.; Malato, Y.; Heuser, A.; Endres, M.; Trautwein, C.; Donath, S. TAT-apoptosis repressor with caspase recruitment domain protein transduction rescues mice from fulminant liver failure. Hepatology 2012, 56, 715–726. [Google Scholar] [CrossRef]
- Huang, Y.Q.; Li, P.Y.; Wang, J.B.; Zhou, H.Q.; Yang, Z.R.; Yang, R.C.; Bai, Z.F.; Wang, L.F.; Li, J.Y.; Liu, H.H. Inhibition of sophocarpine on poly I: C/D-GalN-induced immunological liver injury in mice. Front. Pharmacol. 2016, 7, 256. [Google Scholar] [CrossRef] [Green Version]
- Xu, D.W.; Xu, M.; Jeong, S.; Qian, Y.H.; Wu, H.L.; Xia, Q.; Kong, X.N. The Role of Nrf2 in liver disease: Novel molecular mechanisms and therapeutic approaches. Front. Pharmacol. 2018, 9, 1428. [Google Scholar] [CrossRef] [Green Version]
- Perego, J.; Bourbon, C.; Chasson, L.; Laprie, C.; Spinelli, L.; Gatti, E.; Pierre, P. Guanabenz prevents D-galactosamine/lipopolysaccharide-induced liver damage and mortality. Front. Immunol. 2017, 8, 679. [Google Scholar] [CrossRef] [Green Version]
- Chen, T.P.; Zhu, G.Y.; Meng, X.W.; Zhang, X.X. Recent developments of small molecules with anti-inflammatory activities for the treatment of acute lung injury. Eur. J. Med. Chem. 2020, 207, 112660–223679. [Google Scholar] [CrossRef]
- Wiggers, H.J.; Zaioncz, S.; Cheleski, J.; Mainardes, R.M.; Khalil, N.M. Chapter 7-Curcumin, a multitarget phytochemical: Challenges and perspectives. Stud. Nat. Prod. Chem. 2017, 53, 243–276. [Google Scholar]
- Singh, A.; Singh, J.V.; Rana, A.; Bhagat, K.; Gulati, H.V.; Kumar, R.; Salwan, R.; Bhagat, K.; Kaur, G.; Singh, N.; et al. Monocarbonyl curcumin-based molecular hybrids as potent antibacterial agents. ACS Omega 2019, 4, 11673–11684. [Google Scholar] [CrossRef]
- Chen, L.P.; Li, Q.; Weng, B.X.; Wang, J.B.; Wu, J.Z. Design, synthesis, anti-lung cancer activity, and chemosensitization of tumor-selective MCACs based on ROS-mediated JNK pathway activation and NF-kB pathway inhibition. Eur. J. Med. Chem. 2018, 151, 508–519. [Google Scholar] [CrossRef]
- Dinkova-Kostova, A.T.; Cory, A.H.; Bozak, R.E.; Hicks, R.J.; Cory, J.G. Bis(2-hydroxybenzylidene)acetone, a potent inducer of the phase 2 response, causes apoptosis in mouse leukemia cells through a p53-independent, caspase-mediated pathway. Cancer Lett. 2007, 245, 341–349. [Google Scholar] [CrossRef] [PubMed]
- He, Y.H.; Li, W.; Hu, G.; Sun, H.; Kong, Q. Bioactivities of EF24, a Novel Curcumin Analog: A Review. Front. Oncol. 2018, 8, 614–622. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, H.P.; Xu, T.T.; Qiu, C.Y.; Wu, B.B.; Zhang, Y.L.; Chen, L.F.; Xia, Q.Q.; Li, C.L.; Zhou, B.; Liu, Z.G.; et al. Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats. Eur. J. Med. Chem. 2016, 121, 181–193. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.Q.; Mu, W.W.; Li, P.X.; Liu, G.Y.; Yang, J. Anti-inflammatory activity of ortho-trifluoromethoxy-substituted 4-piperidione-containing mono-carbonyl curcumin derivatives in vitro and in vivo. Eur. J. Pharm. Sci. 2021, 160, 105756. [Google Scholar] [CrossRef]
- Jin, Y.Y.; Wang, H.X.; Yi, K.; Lv, S.X.; Hu, H.Z.; Li, M.Q.; Tao, Y. Applications of nanobiomaterials in the therapy and imaging of acute liver failure. Nano-Micro Lett. 2021, 13, 74–106. [Google Scholar] [CrossRef]
- Karimi, M.; Bahrami, S.; Ravari, S.B.; Zangabad, P.S.; Mirshekari, H.; Bozorgomid, M.; Shahreza, S.; Sori, M.; Hamblin, M.R. Albumin nanostructures as advanced drug delivery systems. Expert Opin. Drug Deliv. 2016, 13, 1609–1623. [Google Scholar] [CrossRef] [Green Version]
- Parodi, A.; Miao, J.X.; Soond, S.M.; Rudzińska, M.; Zamyatnin, A.A., Jr. Albumin nanovectors in cancer therapy and imaging. Biomolecules 2019, 9, 218. [Google Scholar] [CrossRef] [Green Version]
- Li, L.M.; Chen, Y.; Wang, Q.P.; Li, Z.J.; Liu, Z.F.; Hua, X.W.; Han, J.; Chang, C.X.; Wang, Z.P.; Li, D.C. Albumin-encapsulated nanoparticles of naproxen platinum(IV) complexes with inflammation inhibitory competence displaying effective antitumor activities in vitro and in vivo. Int. J. Nanomed. 2021, 16, 5513–5529. [Google Scholar] [CrossRef]
- Zhao, Y.N.; Cai, C.; Liu, M.; Zhao, Y.P.; Wu, Y.S.; Fan, Z.P.; Ding, Z.; Zhang, H.Z.; Wang, Z.N.; Han, J. Drug-binding albumins forming stabilized nanoparticles for co-delivery of paclitaxel and resveratrol: In vitro/in vivo evaluation and binding properties investigation. Int. J. Biol. Macromol. 2020, 153, 873–882. [Google Scholar] [CrossRef]
- Nosrati, H.; Sefidi, N.; Sharafi, A.; Danafar, H.; Manjili, H.K. Bovine serum albumin (BSA) coated iron oxide magnetic nanoparticles as biocompatible carriers for curcumin-anticancer drug. Bioorg. Chem. 2018, 76, 501–509. [Google Scholar] [CrossRef]
- Nosrati, H.; Danafar, H.; Rezaeejam, H.; Gholipour, N.; Rahimi-Nasrabadi, M. Evaluation radioprotective effect of curcumin conjugated albumin nanoparticles. Bioorg. Chem. 2020, 100, 103891. [Google Scholar] [CrossRef]
- Ding, C.F.; Xu, Y.J.; Zhao, Y.N.; Zhong, H.; Luo, X.L. Fabrication of BSA@AuNC-based nanostructures for cell fluoresce imaging and target drug delivery. ACS Appl. Mater. Interfaces 2018, 10, 8947–8954. [Google Scholar] [CrossRef]
- Zhao, Y.N.; Cai, C.; Liu, M.; Zhao, Y.P.; Pei, W.X.; Chu, X.L.; Zhang, H.Z.; Wang, Z.P.; Han, J. An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy. Colloid. Surf. B 2019, 183, 110394. [Google Scholar] [CrossRef]
- Ozer, J.; Ratner, M.; Shaw, M.; Bailey, W.; Schomaker, S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008, 245, 194–205. [Google Scholar] [CrossRef]
- Hayden, M.S.; Ghosh, S. Shared principles in NF-kappaB signaling. Cell 2008, 132, 344–362. [Google Scholar] [CrossRef] [Green Version]
- Hishinuma, I.; Nagakawa, J.I.; Hirota, K.; Miyamoto, K.; Tsukidate, K.; Yamanaka, T.; Katayama, K.I.; Yamatsu, I. Involvement of tumor necrosis factor-α in development of hepatic injury in galactosamine-sensitized mice. Hepatology 1990, 12, 1187–1191. [Google Scholar] [CrossRef]
- Tiegs, G.; Wolter, M.; Wendel, A. Tumor necrosis factor is a terminal mediator in galactosamine/endotoxin-induced hepatitis in mice. Biochem. Pharmacol. 1989, 38, 627–631. [Google Scholar] [CrossRef]
- Jaeschke, H.; Fisher, M.A.; Lawson, J.A.; Simmons, C.A.; Farhood, A.; Jones, D.A. Activation of caspase 3 (CPP32)-like proteases is essential for TNF-α-induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J. Immunol. 1998, 160, 3480–3486. [Google Scholar]
- Thimmulappa, R.K.; Scollick, C.; Traore, K.; Yates, M.; Trush, M.A.; Liby, K.T.; Sporn, M.B.; Yamamoto, M.; Kensier, T.W.; Biswal, S. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-imidazolide. Biochem. Bioph. Res. Com. 2006, 351, 883–889. [Google Scholar] [CrossRef] [Green Version]
- Liu, G.Y.; Jia, C.C.; Han, P.R.; Yang, J. 3,5-Bis(2-fluorobenzylidene)-4-piperidone induce reactive oxygen species-mediated apoptosis in A549 cells. Med. Chem. Res. 2018, 27, 128–136. [Google Scholar] [CrossRef]
- He, S.S.; Lin, Q.; Qu, M.K.; Wang, L.Y.; Deng, L.; Xiao, L.Y.; Zhang, Z.R.; Zhang, L. Liver-targeted co-delivery of entecavir and glycyrrhetinic acid based on albumin nanoparticle to enhance the accumulation of entecavir. Mol. Pharmaceut. 2018, 15, 3953–3961. [Google Scholar] [CrossRef] [PubMed]
NPs | Size (d.nm) | PDI | Zeta (mV) | EE (%) | DLC (%) |
---|---|---|---|---|---|
22 NPs | 209.2 ± 4.2 | 0.310 ± 0.016 | −18.6 ± 0.3 | 99.98 ± 0.01 | 4.19 ± 0.05 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mu, W.; Wang, Q.; Jia, M.; Dong, S.; Li, S.; Yang, J.; Liu, G. Hepatoprotective Effects of Albumin-Encapsulated Nanoparticles of a Curcumin Derivative COP-22 against Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Injury in Mice. Int. J. Mol. Sci. 2022, 23, 4903. https://doi.org/10.3390/ijms23094903
Mu W, Wang Q, Jia M, Dong S, Li S, Yang J, Liu G. Hepatoprotective Effects of Albumin-Encapsulated Nanoparticles of a Curcumin Derivative COP-22 against Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Injury in Mice. International Journal of Molecular Sciences. 2022; 23(9):4903. https://doi.org/10.3390/ijms23094903
Chicago/Turabian StyleMu, Wenwen, Qi Wang, Mingxia Jia, Sijia Dong, Sijie Li, Jie Yang, and Guoyun Liu. 2022. "Hepatoprotective Effects of Albumin-Encapsulated Nanoparticles of a Curcumin Derivative COP-22 against Lipopolysaccharide/D-Galactosamine-Induced Acute Liver Injury in Mice" International Journal of Molecular Sciences 23, no. 9: 4903. https://doi.org/10.3390/ijms23094903